About us

Alexion, AstraZeneca Rare Disease, is the rare disease focused group within AstraZeneca and was formed following the acquisition of Alexion Pharmaceuticals, Inc. in 2021. As a leader in the field of rare diseases, Alexion has been focused for almost 30 years dedicated to serving patients and families affected by rare and serious diseases through the discovery, development and commercialization of life-changing medicines.

Alexion’s research is focused on novel molecules and targets in the complement cascade, with particular focus on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the world serving patients in more than 50 countries.